Diabetes Care in The Netherlands: - Novo Nordisk

More documents

Recommendations

Info

Clear potential in in high quality treatment implementation and andcompliance improvementILLUSTRATIVEPrimary care protocol canbring life expectancy of Type2 patients to normal levelsRegional variances in care patterns arestill high% of Type 2 insulin patient in first line (2008 )Non-compliance significant asdifferent studies indicateArticle:Life expectancy in a largecohort of type 2 diabetespatients treated in primarycareLutgers LH, Gerrits EG,Sluiter WJ, Ubink-VeltmaatLJ, Landman GWD, LinksTP, Gans ROB, Smit AJ,Bilo HJG; (ZODIAC-10).PlosOne 2009;% of insulin patientsZwolle Region Region RegionRegion19 %Region Region% of patients with HbA1c < 7% per health care group in2009 & 201068%68%67%63%61%59%Studies of therapy adherence on theDutch diabetes Type 2 patientsPaes e.a.; 1998:Therapy adherence related to:• Frequency of dosage 66-99%• Prescribed doses 38-79%Cramer; 2004:General Therapy adherence• Type 2 diabetes 36-93%56%Selected care groups in The NetherlandsProfessionals and DVN are developing national primary carebenchmark for diabetes for more insight in practice variationsSource: DiabetesZorgBeter Prof H. Bilo, PoZoB, Kaiser permanente , Diabeteszorg Zorggroepen Nederlandse Huisartspraktijken - van Rutten, Booz & Company analysisSource: DiabetesZorgBeter - Prof H. Bilo, PoZoB, Kaiser permanente, Diabeteszorg Zorggroepen Nederlandse Huisartspraktijken - van Rutten, Booz & Company analysisBooz & Company 14 November 2011Prepared for Novo Nordisk3023
ContentsSummarized findings and recommendationsThe opportunity• Diabetes is a major and underestimated source of medical costs and lost productivity• Diabetes care in The Netherlands has reached a high level of quality, but there is still opportunity for further improvement• Further improving health of patients may lead to EUR 1.5-2 B of economic benefits in 2020The road• Refine economic incentives to encourage integrated care and quality improvement• Engage employers, UWV and participative care in diabetes care• Engage the patient’s social network to support self management• Introduce conditional market access models for new therapies and medication to assess behavioural impactAppendix: list of sources31
Page 6 and 7: SummaryDiabetes is a serious and de
Page 8: diabetes care. Extra compensation w
Page 11 and 12: ContentsSummarized findings and rec
Page 13 and 14: 11Diabetes is a major and underesti
Page 15 and 16: 33Further improving health of of di
Page 17 and 18: 22Recommendation 2: Engage employer
Page 19 and 20: 44Recommendation 4: Introduce condi
Page 21 and 22: Already more than 1M diabetes patie
Page 23 and 24: Costs of of complications and treat
Page 25 and 26: Number of patients reaches ~1.4M in
Page 27 and 28: Increase in lost productivity is dr
Page 29 and 30: Diabetes care clearly improved in t
Page 31: Better compliance can be stimulated
Page 37 and 38: Delaying complications saves medica
Page 39 and 40: LimitedLimitedcollaborationcollabor
Page 41 and 42: Individual quality incentives are l
Page 43 and 44: Recommendation 1: Insurer should in
Page 47 and 48: Labour shortage from late nineties
Page 49 and 50: However, curative and participative
Page 53 and 54: Non-compliance leads to severe comp
Page 55: Facilitated patient networks are su
Page 58 and 59: Recommendation 3:Facilitate network
Page 62 and 63: But new medication could add a lot
Page 66: Booz & Company is a global manageme

Diabetes Care in The Netherlands: - Novo Nordisk

Create successful ePaper yourself

Delete template?

Save as template?